Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.

Turley RS, Tokuhisa Y, Toshimitsu H, Lidsky ME, Padussis JC, Fontanella A, Deng W, Augustine CK, Beasley GM, Davies MA, Dewhirst MW, Tyler DS.

Ann Surg. 2015 Feb;261(2):368-77. doi: 10.1097/SLA.0000000000000635.

2.

Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.

Turley RS, Fontanella AN, Padussis JC, Toshimitsu H, Tokuhisa Y, Cho EH, Hanna G, Beasley GM, Augustine CK, Dewhirst MW, Tyler DS.

Clin Cancer Res. 2012 Jun 15;18(12):3328-39. doi: 10.1158/1078-0432.CCR-11-3000. Epub 2012 Apr 10.

3.

Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.

Beasley GM, Riboh JC, Augustine CK, Zager JS, Hochwald SN, Grobmyer SR, Peterson B, Royal R, Ross MI, Tyler DS.

J Clin Oncol. 2011 Mar 20;29(9):1210-5. doi: 10.1200/JCO.2010.32.1224. Epub 2011 Feb 22.

4.

Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.

Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS.

Am J Surg. 2004 Nov;188(5):532-7.

PMID:
15546565
5.

Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.

Augustine CK, Yoshimoto Y, Gupta M, Zipfel PA, Selim MA, Febbo P, Pendergast AM, Peters WP, Tyler DS.

Cancer Res. 2008 May 15;68(10):3777-84. doi: 10.1158/0008-5472.CAN-07-5949.

6.

A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.

Beasley GM, McMahon N, Sanders G, Augustine CK, Selim MA, Peterson B, Norris R, Peters WP, Ross MI, Tyler DS.

Cancer. 2009 Oct 15;115(20):4766-74. doi: 10.1002/cncr.24509.

7.

A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.

Beasley GM, Speicher P, Augustine CK, Dolber PC, Peterson BL, Sharma K, Mosca PJ, Royal R, Ross M, Zager JS, Tyler DS.

Ann Surg Oncol. 2015 Jan;22(1):287-94. doi: 10.1245/s10434-014-3887-z. Epub 2014 Aug 22.

8.

SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.

Tokuhisa Y, Lidsky ME, Toshimitsu H, Turley RS, Beasley GM, Ueno T, Sharma K, Augustine CK, Tyler DS.

Ann Surg Oncol. 2014 Mar;21(3):1024-30. doi: 10.1245/s10434-013-3387-6. Epub 2013 Nov 27.

9.

Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.

Yoshimoto Y, Augustine CK, Yoo JS, Zipfel PA, Selim MA, Pruitt SK, Friedman HS, Ali-Osman F, Tyler DS.

Mol Cancer Ther. 2007 May;6(5):1492-500. Epub 2007 May 4.

10.

Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.

Pagani E, Falcinelli S, Pepponi R, Turriziani M, Caporaso P, Caporali S, Bonmassar E, D'Atri S.

Int J Oncol. 2007 Feb;30(2):443-51.

PMID:
17203227
11.

Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.

Toshimitsu H, Yoshimoto Y, Augustine CK, Padussis JC, Yoo JS, Angelica Selim M, Pruitt SK, Friedman HS, Ali-Osman F, Tyler DS.

Ann Surg Oncol. 2010 Aug;17(8):2247-54. doi: 10.1245/s10434-010-0971-x. Epub 2010 Feb 24.

PMID:
20182810
12.

Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.

Augustine CK, Toshimitsu H, Jung SH, Zipfel PA, Yoo JS, Yoshimoto Y, Selim MA, Burchette J, Beasley GM, McMahon N, Padussis J, Pruitt SK, Ali-Osman F, Tyler DS.

Mol Cancer Ther. 2010 Jul;9(7):2090-101. doi: 10.1158/1535-7163.MCT-10-0073. Epub 2010 Jun 22.

13.

Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.

Yang J, Zaja-Milatovic S, Thu YM, Lee F, Smykla R, Richmond A.

Mol Cancer Ther. 2009 Mar;8(3):636-47. doi: 10.1158/1535-7163.MCT-08-0749. Epub 2009 Mar 10.

14.

Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.

Ueno T, Ko SH, Grubbs E, Yoshimoto Y, Augustine C, Abdel-Wahab Z, Cheng TY, Abdel-Wahab OI, Pruitt SK, Friedman HS, Tyler DS.

Mol Cancer Ther. 2006 Mar;5(3):732-8.

15.

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.

Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J, Garbe C, Meier F.

J Invest Dermatol. 2009 Jun;129(6):1500-15. doi: 10.1038/jid.2008.379. Epub 2008 Dec 11.

16.

Metaiodobenzylguanidine and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma.

Canter RJ, Zhou R, Kesmodel SB, Zhang Y, Heitjan DF, Glickson JD, Leeper DB, Fraker DL.

Ann Surg Oncol. 2004 Mar;11(3):265-73.

PMID:
14993021
17.

NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.

Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.

Cancer Lett. 2015 Oct 10;367(1):58-68. doi: 10.1016/j.canlet.2015.07.007. Epub 2015 Jul 15.

PMID:
26188279
18.

IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.

Ramcharan R, Aleksic T, Kamdoum WP, Gao S, Pfister SX, Tanner J, Bridges E, Asher R, Watson AJ, Margison GP, Woodcock M, Repapi E, Li JL, Middleton MR, Macaulay VM.

Oncotarget. 2015 Nov 24;6(37):39877-90. doi: 10.18632/oncotarget.5631.

19.

A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.

Bauer TW, Gutierrez M, Dudrick DJ, Li J, Blair IA, Menon C, Fraker DL.

Surgery. 2003 Apr;133(4):420-8.

PMID:
12717360
20.

Loss of T-cadherin (CDH-13) regulates AKT signaling and desensitizes cells to apoptosis in melanoma.

Bosserhoff AK, Ellmann L, Quast AS, Eberle J, Boyle GM, Kuphal S.

Mol Carcinog. 2014 Aug;53(8):635-47. doi: 10.1002/mc.22018. Epub 2013 Apr 26.

PMID:
23625515

Supplemental Content

Support Center